510(k) · Cleared
ClearedApollo TMS Therapy System;Apollo light TMS Therapy System
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Mag & More GmbH · OBP Transcranial Magnetic Stimulator
Cleared on May 22, 2026 as substantially equivalent to K220127 (Neuronetics, Inc., 2022) and 3 other predicates after a 92-day review. Its family tree reaches back 13 generations to 2008.
- Decided
- May 22, 2026
- Review
- 92 days
- Class
- Class II
- Product code
- OBP
- Recalls
- None
- Predicates
- 4
Its longest line of descent runs back 13 generations to DEN070003 (2008). 33 ancestors in all. No later device cites it as a predicate yet.
- Root · 13 generations backDEN070003 Neurostar TMS SystemNeuronetics · 2008
- 9 generations between
- 3 generations backK230029 NeuroStar Advanced Therapy System (Version 3.7)Neuronetics · 2023
- 2 generations backK231926 NeuroStar Advanced Therapy System (All previously cleared models)Neuronetics, Inc. · 2024 · Recalled
- 1 generation backK243700 Apollo TMS Therapy SystemMag & More GmbH · 2025
- This deviceK260560 Apollo TMS Therapy System;Apollo light TMS Therapy SystemMag & More GmbH · 2026
Show all 13 generations
- Root · 13 generations backDEN070003 Neurostar TMS SystemNeuronetics · 2008
- 12 generations backK083538 Neurostar TMS Therapy System, Model 1.1Neuronetics · 2008 · Recalled
- 11 generations backK130233 Neurostar TMS Therapy SystemNeuronetics · 2013
- 10 generations backK133408 Neurostar TMS Therapy SystemNeuronetics · 2014
- 9 generations backK143531 Rapid Therapy SystemMagstim Company Limited · 2015 · Recalled
- 8 generations backK160309 Neurosoft TMSTeleemg, LLC · 2016
- 7 generations backK171967 MagVita TMS Therapy SystemTonica Elektronik A/S · 2017
- 6 generations backK173620 Mag Vita TMS Therapy System w/Theta Burst StimulationTonica Elektronik A/S · 2018
- 5 generations backK193006 MagVenture TMS Therapy – for treatment of OCD, MagVenture TMS…Tonica Elektronik A/S · 2020
- 4 generations backK212289 NeuroStar Advanced Therapy for adjunctive treatment of OCD…Neuronetics, Inc. · 2022
- 3 generations backK230029 NeuroStar Advanced Therapy System (Version 3.7)Neuronetics · 2023
- 2 generations backK231926 NeuroStar Advanced Therapy System (All previously cleared models)Neuronetics, Inc. · 2024 · Recalled
- 1 generation backK243700 Apollo TMS Therapy SystemMag & More GmbH · 2025
- This deviceK260560 Apollo TMS Therapy System;Apollo light TMS Therapy SystemMag & More GmbH · 2026
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −13 | DEN070003 | Neurostar TMS System | Neuronetics | 2008 | — |
| −12 | K083538 | Neurostar TMS Therapy System, Model 1.1 | Neuronetics | 2008 | 1 |
| −11 | K130233 | Neurostar TMS Therapy System | Neuronetics | 2013 | — |
| −10 | K133408 | Neurostar TMS Therapy System | Neuronetics | 2014 | — |
| −9 | K143531 | Rapid Therapy System | Magstim Company Limited | 2015 | 3 |
| −8 | K160309 | Neurosoft TMS | Teleemg, LLC | 2016 | — |
| −7 | K171967 | MagVita TMS Therapy System | Tonica Elektronik A/S | 2017 | — |
| −6 | K173620 | Mag Vita TMS Therapy System w/Theta Burst Stimulation | Tonica Elektronik A/S | 2018 | — |
| −5 | K193006 | MagVenture TMS Therapy – for treatment of OCD, MagVenture TMS Therapy system | Tonica Elektronik A/S | 2020 | — |
| −4 | K212289 | NeuroStar Advanced Therapy for adjunctive treatment of OCD, NeuroStar Advanced… | Neuronetics, Inc. | 2022 | — |
| −3 | K230029 | NeuroStar Advanced Therapy System (Version 3.7) | Neuronetics | 2023 | — |
| −2 | K231926 | NeuroStar Advanced Therapy System (All previously cleared models) | Neuronetics, Inc. | 2024 | 1 |
| −1 | K243700 | Apollo TMS Therapy System | Mag & More GmbH | 2025 | — |
| 0 (this device) | K260560 | Apollo TMS Therapy System;Apollo light TMS Therapy System | Mag & More GmbH | 2026 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2013 | 1 | 0 |
| 2015 | 1 | 0 |
| 2016 | 2 | 0 |
| 2017 | 6 | 0 |
| 2018 | 4 | 0 |
| 2019 | 2 | 0 |
| 2020 | 1 | 0 |
| 2021 | 1 | 0 |
| 2022 | 1 | 0 |
| 2024 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in OBP? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new OBP device
- #1 K251119 MagVenture TMS Therapy Systemscore 21.8 · 11 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (4)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K220127 | NeuroStar TMS Therapy System, NeuroStar Advanced Therapy System, NeuroStar, NeuroStar…Summary page 5…etic Stimulation Device 21 CFR 882.5805, Product Code OBP Predicate Device: NeuroStar Advanced Therapy System (K220127) Apollo TMS Therapy System (K180313, K232639, K243700) Intended Use The Apollo TMS Ther… | 2022 |
| * | K180313 | Apollo TMS Therapy SystemSummary page 5…805, Product Code OBP Predicate Device: NeuroStar Advanced Therapy System (K220127) Apollo TMS Therapy System (K180313, K232639, K243700) Intended Use The Apollo TMS Therapy System is indicated for the treatment of depressive episodes and for d… | 2018 |
| * | K232639 | Apollo TMS Therapy SystemSummary page 5…uct Code OBP Predicate Device: NeuroStar Advanced Therapy System (K220127) Apollo TMS Therapy System (K180313, K232639, K243700) Intended Use The Apollo TMS Therapy System is indicated for the treatment of depressive episodes and for decreasing… | 2024 |
| * | K243700 | Apollo TMS Therapy SystemSummary page 5…OBP Predicate Device: NeuroStar Advanced Therapy System (K220127) Apollo TMS Therapy System (K180313, K232639, K243700) Intended Use The Apollo TMS Therapy System is indicated for the treatment of depressive episodes and for decreasing anxiety… | 2025 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 18 years and passes through 6 companies; a new generation was cleared every 1.1 years on median.
- 6 of the 33 ancestors have a recall of any class.
- 4 other devices also cite its predicate K220127.
How does its category compare?
All OBP devicesOBP Transcranial Magnetic Stimulator: FDA decisions, review times, recalls and adverse event reports over 20 years. 2026, this device’s year, is highlighted.
FDA decisions per year · OBP
12in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · OBP
125in 2025
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · OBP
1in 2018
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · OBP
81in 2025
MAUDE reports naming product code OBP, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 2 | — | 0 | 0 |
| 2009 | 0 | — | 1 | 3 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 5 |
| 2012 | 0 | — | 0 | 3 |
| 2013 | 2 | — | 0 | 1 |
| 2014 | 1 | — | 0 | 0 |
| 2015 | 2 | — | 0 | 3 |
| 2016 | 3 | 101 | 0 | 6 |
| 2017 | 8 | 73 | 0 | 3 |
| 2018 | 4 | 144 | 1 | 6 |
| 2019 | 3 | 156 | 0 | 12 |
| 2020 | 1 | — | 0 | 12 |
| 2021 | 5 | 132 | 0 | 15 |
| 2022 | 6 | 168 | 0 | 59 |
| 2023 | 7 | 119 | 0 | 43 |
| 2024 | 5 | 266 | 0 | 50 |
| 2025 | 12 | 125 | 0 | 81 |
| 2026 | 8 | 176 | 1 | — |
What is it indicated for?
The Apollo TMS Therapy System is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.
Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.
https://510kreport.com/device/K260560 · printed Nov 6, 2026
Cite this page
510(k) Report. “K260560: Apollo TMS Therapy System;Apollo light TMS Therapy System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K260560
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded Oct 30, 2026
- Summary read Oct 30, 2026 (extraction version 2d9447fa9ea4)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026